Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 30.97 USD 1.57% Market Closed
Market Cap: 3.4B USD
Have any thoughts about
Novocure Ltd?
Write Note

Operating Margin
Novocure Ltd

-27.2%
Current
-24%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.2%
=
Operating Profit
-156.9m
/
Revenue
577.7m

Operating Margin Across Competitors

Country JE
Market Cap 3.3B USD
Operating Margin
-27%
Country US
Market Cap 199B USD
Operating Margin
17%
Country US
Market Cap 191.3B USD
Operating Margin
26%
Country US
Market Cap 141.3B USD
Operating Margin
22%
Country US
Market Cap 134.2B USD
Operating Margin
18%
Country IE
Market Cap 104.6B USD
Operating Margin
19%
Country US
Market Cap 65.6B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.5B USD
Operating Margin
28%
Country CN
Market Cap 307.8B CNY
Operating Margin
36%
Country US
Market Cap 36.3B USD
Operating Margin
13%
No Stocks Found

Novocure Ltd
Glance View

Market Cap
3.3B USD
Industry
Health Care

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

NVCR Intrinsic Value
25.58 USD
Overvaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.2%
=
Operating Profit
-156.9m
/
Revenue
577.7m
What is the Operating Margin of Novocure Ltd?

Based on Novocure Ltd's most recent financial statements, the company has Operating Margin of -27.2%.